logo
  

BioDelivery Sciences International (BDSI) Sank After Phase 3 Study Failed

BioDelivery Sciences International (BDSI) announced Monday morning that its Phase 3 clinical study of Clonidine Topical Gel did not meet its primary endpoint.

BioDelivery Sciences International gapped open sharply lower Monday, but was range-bound for the majority of the session. Shares finished with a loss of 3.38 at $10.51, on the highest volume in over 8 months. The stock sank to over a 9 1/2 month low.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.

First quarter growth data from China gained the maximum focus this week as trends in the massive emerging economy impact its trading partners. Elsewhere, the IMF released its latest global macroeconomic projections. Read our story to find out why comments from the Fed Chair Powell damped rate cut expectations. Meanwhile, there was some survey data that kindled hopes of a recovery in manufacturing. In the U.K., inflation data for March revealed some confusing trends.

View More Videos
Follow RTT